CompanySweeper

Evidence-backed Indian equities

The Daily Sweep

One current development, the listed companies it may reach, and the evidence that would prove—or break—the connection.

Latest

Sun Pharma’s MFN deal turns India’s pharma advantage into a pricing test

Sterile pharmaceutical vials moving along a clean manufacturing line beside stainless steel processing equipment and a port beyond
A pharmaceutical production line frames the supply-chain and localisation trade-off behind the new US pricing agreements.

The reported tariff reprieve has a price: lower US Medicaid prices. The companies best placed to absorb that trade-off are the ones with regulated-market access, integrated supply and room to manufacture closer to customers.

6 min readRead article →

Earlier research

Browse every evidence-backed company landscape.